Stocks · News reference
Celcuity Inc. announced its financial results for the third quarter ended September 30, 2026, alongside updates on the commercial launch of REVTORPYK™ and ongoing clinical trial progress.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The FDA has accepted Celcuity's supplemental New Drug Application (sNDA) for REVTORPYK™ (gedatolisib) to treat HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer.
Analysts raised targets for Magnite, Airbnb and Choice Hotels; cut targets for Unusual Machines, DraftKings, PDD and TeraWulf. DKNG and PDD downgraded.
HC Wainwright & Co. has reaffirmed its 'Buy' rating on Celcuity Inc. while adjusting the price target to $150 from $155.